Ethical considerations in psychopharmacological research involving children and adolescents

被引:28
作者
Vitiello, B [1 ]
机构
[1] NIMH, Child & Adolescent Treatment & Prevent Intervent, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
ethics; psychopharmacology; children; research;
D O I
10.1007/s00213-003-1400-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale. Increased community utilization of psychotropic medications among children has brought attention to pediatric psychopharmacology research and associated ethical issues. Objectives. To discuss ethical aspects of child participation in psychopharmacology protocols. Methods. Selective review of relevant scientific and regulatory literature. Results. Efficacy and safety of psychotropics in children cannot be entirely inferred from adult data and direct participation of children in research is necessary. Child research must follow special regulations that are in addition to those common to all human research. For research with prospect of direct benefit, a critical factor is whether the risk/benefit ratio is favorable to the participating child. For research without such a prospect, the concepts of minimal risk and minor increase over minimal risk apply. However, the interpretation and application of these principles to specific protocols vary across settings and among ethics committees. Thus far, little empirical investigation has been conducted on children and parents' motivation for research participation, effectiveness of the informed consent and assent procedures, possibility of persistent consequences of exposure to experimental treatments and placebo, and validation of the concepts of minimal risk and minor increase over minimal risk.<LF>Conclusions. Research on human subject issues relevant to child participation is a promising approach to improving ethical methods and procedures of pediatric psychopharmacology.
引用
收藏
页码:86 / 91
页数:6
相关论文
共 26 条
[1]  
Agency for Health Care Policy and Research, 1999, AHCPR PUBL, V99-0034
[2]  
[Anonymous], 1998, Fed Regist, V63, P66631
[3]  
[Anonymous], 1995, Pediatrics, V95, P286
[4]   National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders [J].
Charney, DS ;
Nemeroff, CB ;
Lewis, L ;
Laden, SK ;
Gorman, JM ;
Laska, EM ;
Borenstein, M ;
Bowden, CL ;
Caplan, A ;
Emslie, GJ ;
Evans, DL ;
Geller, B ;
Grabowski, LE ;
Herson, J ;
Kalin, NH ;
Keck, PE ;
Kirsch, I ;
Krishnan, KRR ;
Kupfer, DJ ;
Makuch, RW ;
Miller, FG ;
Pardes, H ;
Post, R ;
Reynolds, MM ;
Roberts, L ;
Rosenbaum, JF ;
Rosenstein, DL ;
Rubinow, DR ;
Rush, AJ ;
Ryan, ND ;
Sachs, GS ;
Schatzberg, AF ;
Solomon, S .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (03) :262-270
[5]   Cognitive-behavioral treatment of adolescent depression: Efficacy of acute group treatment and booster sessions [J].
Clarke, GN ;
Rohde, P ;
Lewinsohn, PM ;
Hops, H ;
Seeley, JR .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1999, 38 (03) :272-279
[6]   Psychotropic drug use in very young children [J].
Coyle, JT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (08) :1059-1060
[7]   What makes clinical research ethical? [J].
Emanuel, EJ ;
Wendler, D ;
Grady, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (20) :2701-2711
[8]  
Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031
[9]  
EMSLIE GJ, 2000, 47 ANN M AM AC CHILD
[10]   PHENOBARBITAL FOR FEBRILE SEIZURES - EFFECTS ON INTELLIGENCE AND ON SEIZURE RECURRENCE [J].
FARWELL, JR ;
LEE, YJ ;
HIRTZ, DG ;
SULZBACHER, SI ;
ELLENBERG, JH ;
NELSON, KB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (06) :364-369